Back to Trials
NCT06326996EARLY_PHASE1Recruiting

Thiamine Intervention and Coronary Artery Bypass Grafting

University of California, Los Angeles

Start Date

10/10/2024

Completion Date

9/30/2026

Summary

The purpose of this study is to gain a better understanding of the association between brain changes and cognitive deficits in coronary heart disease (CHD) patients undergoing coronary artery bypass grafting (CABG) and whether a low-cost thiamine intervention can be used to reduce post-CABG cognitive issues in CHD subjects.

Detailed Description

Using a two-group, double-blind randomized, longitudinal study design, 52 coronary heart disease (CHD) patients undergoing coronary artery bypass grafting (CABG) (ages 60-80 years; 26 thiamine treatment and 26 placebo) will participate in cognitive assessment and evaluation of blood thiamine, lactate, and inflammatory marker levels. The investigators propose that thiamine infusion will help in reducing lactate and inflammatory marker levels, as observed in other conditions. The findings from this study might serve as a novel and innovative treatment strategy for protection against declining cognition, and hence better outcomes, and improved quality of life and daily activities. This clinical trial study will provide required data regarding the benefits of a low-cost thiamine intervention that could be implemented on a large-scale clinical trial to reduce post-CABG cognitive deficits in older CHD, and thus, decrease early dementia, improve social function, increase quality of life and daily activities, and reduce healthcare costs in this serious older CHD patient population.

Eligibility Criteria

Age Range: 60 years to 80 years

Inclusion Criteria: * Patients with Coronary Heart Disease (CHD) scheduled for Bypass Grafting (CABG) * Thiamine deficiency before CABG * European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) \>1.5% * Off-pump surgery Exclusion Criteria: * Dementia at baseline \[Montreal Cognitive Assessment (MoCA) \<21 within 5 days before CABG\] * Current in-take of thiamine * Known thiamine allergy * Uncontrolled blood glucose levels * Unable to give consent due to illness * History of hyperlactatemia * Recent (within several years and/or up to the judgment of the PI/co-PIs) cerebral incidents (seizure or head trauma resulting in loss of consciousness and/or concussion) * Stroke * Diagnosed psychiatric diseases (clinical depression, schizophrenia, manic-depression) * Patients with history of alcohol or substance abuse * Acute or chronic infections (tuberculosis, hepatitis, or encephalopathy) * Diagnosed neuro-degenerative diseases (Alzheimer's or Parkinson's disease) * Chronic immunodeficiency (including HIV) * Congenital brain deficits will also be excluded

Interventions

DRUG

Thiamine

DRUG

Placebo

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Coronary Heart DiseaseCoronary Artery Bypass Grafting

Locations

UCLA

Los Angeles, California 90095

United States